Chao Family Comprehensive Cancer Center Clinical Trials: Ovarian Cancer |
| Protocol# |
Principal
Investigator |
Title |
| UCI 04-33 |
Monk |
An Open-Label, Single-Arm, Phase II Study of IV Weekly (Days 1& 8 every 21 days
(HYCAMTIN in Combination with Carboplatin (Day 1 every 21 days) as Second Line
Therapy in Subjects with Potentially Platinum-Sensitive Relapsed Ovarian Cancer |
| GOG 0218 |
Burger |
A Phase III Trial of Carboplatin and Palitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women with Newly Diagnosed, Previously Untreated, Suboptimal Advanced Stage Epithelial Ovarian and Primary Peritoneal Cancer |
| UCI 05-61 |
Monk |
A Pilot Phase II Study Evaluating the Combination of Oxaliplatin and Docetaxel with Bevacizumab as First Line Therapy in Patients with FIGO Stage IB-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma |
| GOG 199 |
Burger |
Prospective Study of Risk-Reducing Salpingo-oophorectomy and Longitundinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer |
| GOG 146-Q |
Burger |
Randomized Phase II Evaluation of Topotecan Administered
Daily X 5 Every 3 Weeks vs. Weekly Topotecan in the
Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian
Tube or Primary Peritoneal Cancer |
| GOG 212 |
Burger |
A Randomized Phase III Trial of Maintenance of
Chemotherapy Comparing 12, Monthly Cycles of Single
Agent Paclitaxel or Xyotax Versus No Treatment Until
Documented Relapse In Women with Advanced Ovarian or
Primary Peritoneal Cancer Who Achieve A Complete Clinical
Response to Primary Platinum/Taxane Chemotherapy |
| GOG 190 |
Burger |
An Exploratory Evaluation of Fenretinide (4-HPR) as a Chemopreventive Agent for Ovarian Carcinoma |
| GOG 9917 |
Burger |
A Dose-Escalating Phase I Study with an Expanded Cohort to Assess the Feasibility of Intraperitoneal Carboplatin and Intravenous Paclitaxel in Patients with Previously Untreated Epithelial Ovarian Primary Peritoneal or Fallopian Tube Carcinoma
|
For additional information on open UCI clinical trials please call toll-free 1-877-UC-STUDY or email ucstudy@uci.edu.
